EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Koivunen, 2008, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res, 14, 4275, 10.1158/1078-0432.CCR-08-0168 Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993 Wong, 2009, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer, 115, 1723, 10.1002/cncr.24181 Inamura, 2008, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers, J Thorac Oncol, 3, 13, 10.1097/JTO.0b013e31815e8b60 Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, 1190, 10.1016/j.cell.2007.11.025 Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, 15, 5216, 10.1158/1078-0432.CCR-09-0802 Inamura, 2009, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Mod Pathol, 22, 508, 10.1038/modpathol.2009.2 Takeuchi, 2009, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer, Clin Cancer Res, 15, 3143, 10.1158/1078-0432.CCR-08-3248 Boland, 2009, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas, Hum Pathol, 40, 1152, 10.1016/j.humpath.2009.01.012 Sun, 2010, Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases, J Clin Oncol, 28, 4616, 10.1200/JCO.2010.29.6038 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Kwak, 2009, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.3509 Takahashi, 2010, Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene, Ann Surg Oncol, 17, 889, 10.1245/s10434-009-0808-7 Zhang, 2010, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Mol Cancer, 9, 188, 10.1186/1476-4598-9-188 Wu, 2008, Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma, Eur Respir J, 32, 924, 10.1183/09031936.00167407 Wu, 2008, First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer, Am J Respir Crit Care Med, 178, 847, 10.1164/rccm.200803-389OC Wu, 2008, Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response, Clin Cancer Res, 14, 4877, 10.1158/1078-0432.CCR-07-5123 Wu, 2008, Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern, Oncologist, 13, 1276, 10.1634/theoncologist.2008-0093 Travis, 2004 Goldstraw, 2007, The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours, J Thorac Oncol, 2, 706, 10.1097/JTO.0b013e31812f3c1a Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Mitsudomi, 2005, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, J Clin Oncol, 23, 2513, 10.1200/JCO.2005.00.992 Sasaki, 2010, The biology and treatment of EML4-ALK non-small cell lung cancer, Eur J Cancer, 46, 1773, 10.1016/j.ejca.2010.04.002 Takano, 2008, EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan, J Clin Oncol, 26, 5589, 10.1200/JCO.2008.16.7254 Yang, 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, J Clin Oncol, 26, 2745, 10.1200/JCO.2007.15.6695 Wu, 2008, Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications, Cancer, 113, 3199, 10.1002/cncr.23925 Suzuki, 2005, Epidermal growth factor receptor expression status in lung cancer correlates with its mutation, Hum Pathol, 36, 1127, 10.1016/j.humpath.2005.08.007 Bae, 2007, EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients, Cancer Genet Cytogenet, 173, 107, 10.1016/j.cancergencyto.2006.10.007 Wang, 1998, Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome, J Cancer Res Clin Oncol, 124, 517, 10.1007/s004320050208 Camidge, 2011, Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed, J Thorac Oncol, 6, 774, 10.1097/JTO.0b013e31820cf053 Lee, 2011, Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer, J Thorac Oncol, 6, 1474, 10.1097/JTO.0b013e3182208fc2 Choi, 2008, Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer, Cancer Res, 68, 4971, 10.1158/0008-5472.CAN-07-6158 Mino-Kenudson, 2010, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry, Clin Cancer Res, 16, 1561, 10.1158/1078-0432.CCR-09-2845 Paik, 2011, Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization, J Thorac Oncol, 6, 466, 10.1097/JTO.0b013e31820b82e8